Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Public ClinicalTrials.gov record NCT04115293. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.
Study identification
- NCT ID
- NCT04115293
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 174 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 74 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 17, 2019 (Actual)
- Primary completion
- Dec 30, 2021 (Actual)
- Completion
- Dec 30, 2021 (Actual)
- Last update posted
- Jul 16, 2025
2019 – 2021
United States locations
- U.S. sites
- 37
- U.S. states
- 27
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 41: Diagnostic and Medical Clinic | Mobile | Alabama | 36604 | — |
| Site 116: Neuromuscular Clinic and Research Center | Phoenix | Arizona | 85028 | — |
| Site 4: University of Southern California | Los Angeles | California | 90033 | — |
| Site 31: University of California Irvine | Orange | California | 92868 | — |
| Site 220: Investigator Site | Pasadena | California | 91101 | — |
| Site 160: Forbes Norris MDA/ALS Research and Treatment Center | San Francisco | California | 94115 | — |
| Site 24: Yale University | New Haven | Connecticut | 06510 | — |
| Site 27: George Washington University | Washington D.C. | District of Columbia | 20037 | — |
| Site 182: Gelasio Baras Neurology | Miami | Florida | 33175 | — |
| Site 25: University of South Florida | Tampa | Florida | 33612 | — |
| Site 135: Augusta University Medical Center | Augusta | Georgia | 30912 | — |
| Site 176: Hawaii Pacific Neuroscience | Honolulu | Hawaii | 96817 | — |
| Site 188: North Shore Medical Group - Glenview | Glenview | Illinois | 60026-1339 | — |
| Site 156: Indiana University Health Neuroscience Center | Indianapolis | Indiana | 46202 | — |
| Site 32: Kansas University Medical Center Research Institute | Kansas City | Kansas | 66160 | — |
| Site 221: Neurology Center of New England | Foxborough | Massachusetts | 02035 | — |
| Site 33: Detroit medical Center - University Health Center | Detroit | Michigan | 48202 | — |
| Site 49: Michigan State University | East Lansing | Michigan | 48824 | — |
| Site 127: University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Site 134: Neurology and Sleep Disorders Clinic | Columbia | Missouri | 65212 | — |
| Site 117: Las Vegas Clinic | Las Vegas | Nevada | 89145 | — |
| Site 123: Northwell Health Neuroscience Institute | Great Neck | New York | 11021 | — |
| Site 23: Hospital for Special Surgery | New York | New York | 10021 | — |
| Site 47: Mount Sinai Hospital | New York | New York | 10029 | — |
| Site 22: University of North Carolina | Chapel Hill | North Carolina | 27599 | — |
| Site 15: Duke University | Durham | North Carolina | 27710 | — |
| Site 122: Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Site 38: Ohio State University | Columbus | Ohio | 43210 | — |
| Site 40: Allegheny Neurological Associates | Pittsburgh | Pennsylvania | 15212 | — |
| Site 128: Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Site 185: Neurology Clinic Cordova | Cordova | Tennessee | 38018 | — |
| Site 131: Austin Neuromuscular Center | Austin | Texas | 78756 | — |
| Site 19: University of Texas Southwestern | Dallas | Texas | 75390 | — |
| Site 39: University of Utah | Salt Lake City | Utah | 84132 | — |
| Site 164: University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
| Site 154: University of Washington | Seattle | Washington | 98195 | — |
| Site 45: Center for Neurological Disorders | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04115293, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 16, 2025 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04115293 live on ClinicalTrials.gov.